Article Impact Level: HIGH Data Quality: STRONG Summary of Biosensors and Bioelectronics, 116932. https://doi.org/10.1016/j.bios.2024.116932 Mete Aslan et al.
Points
- A novel label-free digital detection platform, PD-IRIS, is introduced for infectious disease diagnostics. It combines high sensitivity with ease of use for point-of-care (POC) settings.
- PD-IRIS uses Interferometric Reflectance Imaging Sensor (IRIS) technology, offering enhanced signal sensitivity and eliminating the need for time-consuming scans through a single-image optical signature of target nanoparticles.
- Applied to detecting the Monkeypox virus (MPXV), PD-IRIS achieved a detection limit of 200 PFU/ml, outperforming traditional ELISA methods, and demonstrated specificity against other viruses like HSV-1 and Cowpox.
- This platform allows for rapid, sensitive, and specific pathogen detection, with promising implications for diagnosing Mpox and other infectious diseases at the POC level.
- PD-IRIS’s modularity supports multiplex pathogen detection, and it will be adaptable for other infectious agents as high-affinity ligands become available, advancing clinical diagnostics accessibility and efficiency.
Summary
This research introduces a novel label-free digital detection platform for infectious disease diagnostics, combining laboratory-based digital methods’ high sensitivity and specificity with the affordability and ease of use required for point-of-care (POC) technologies. The platform utilizes Interferometric Reflectance Imaging Sensor (IRIS) technology, which leverages light interference from an optically transparent thin film, offering enhanced signal sensitivity through shot-noise-limited operation and signal averaging. The latest development, called Pixel-Diversity IRIS (PD-IRIS), improves upon the previous ‘Single-Particle’ IRIS (SP-IRIS) by enabling the construction of optical signatures of target nanoparticles (whole viruses) from a single image, eliminating the need for the time-consuming z-scan process.
PD-IRIS was applied to the detection of the Monkeypox virus (MPXV), the causative agent of Mpox infection, demonstrating a limit-of-detection (LOD) of 200 PFU/ml (~3.3 attomolar), which outperforms the laboratory-based ELISA comparator (LOD 1800 PFU/ml). MPXV detection was achieved using anti-A29 monoclonal antibody (mAb 69-126-3), which captured the virus on Protein G spots on sensor chips. The specificity of PD-IRIS was further validated by testing against other viruses, including Herpes simplex virus, type 1 (HSV-1), and Cowpox virus (CPXV), showcasing the technology’s robustness in distinguishing between different pathogens.
This work highlights the potential of PD-IRIS for rapid, highly sensitive, and specific pathogen detection at POC, with significant implications for Mpox and other infectious diseases. PD-IRIS is a modular technology that can be adapted for multiplex detection of various pathogens, provided high-affinity ligands are available to capture their surface antigens. This advancement paves the way for more accessible and efficient diagnostic tools in clinical settings.
Link to the article: https://www.sciencedirect.com/science/article/pii/S0956566324009394
References Aslan, M., Seymour, E., Brickner, H., Clark, A. E., Celebi, I., Townsend, M. B., Satheshkumar, P. S., Riley, M., Carlin, A. F., Ünlü, M. S., & Ray, P. (2024). A label-free optical biosensor-based point-of-care test for the rapid detection of monkeypox virus. Biosensors and Bioelectronics, 116932. https://doi.org/10.1016/j.bios.2024.116932
